Pelvic Inflammatory Disease Clinical Trial
Official title:
A Randomized, Double-blind, Positive-Controlled Study to Evaluate the Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases
Randomized, double blind and positive-controlled clinical trial to assess the efficacy and safety of Fuke Qianjin Capsule compared to Doxycycline Hyclate Tablet in patients with mild to medium PID and its sequalae.
Study participants will be randomly assigned to Test or Control group and the following schedule will be followed Test group: metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days. Control group: metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days. Fuke Qianjin Capsules and their simulants are taken as 2 capsules at a time, 3 times a day, orally after breakfast, lunch and dinner, respectively; Metronidazole Tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively; Doxycycline Hyclate Tablet and their simulants are taken as 1 tablet (0.1 g/tablet, Doxycycline Hyclate Tablet calculated as C22H24N2O8) at a time, twice a day, at the same time as breakfast and dinner, respectively. Scoring pain, symptoms, local signs, routine leucorrhea, cervical secretions, gynaecological B-ultrasound will be examined before the enrollment and after study completion. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03391440 -
A Trial to Assess the Efficacy and Safety of Morinidazole in Women With Pelvic Inflammatory Disease
|
Phase 4 | |
Completed |
NCT01671280 -
Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
|
N/A | |
Completed |
NCT00115388 -
Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease
|
N/A | |
Not yet recruiting |
NCT02972151 -
Clinical Research of TCM on Pelvic Inflammatory Disease Sequelae
|
Phase 2 | |
Completed |
NCT01236131 -
The Role of Novel Organisms in Acute Endometritis
|
N/A | |
Completed |
NCT01160640 -
The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)
|
Phase 2 | |
Active, not recruiting |
NCT03994055 -
Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer
|
N/A | |
Completed |
NCT00871494 -
Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
|
Phase 3 | |
Completed |
NCT00783419 -
Rate of Pelvic Inflammatory Disease at St. Michael's Hospital
|
||
Completed |
NCT01799356 -
Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials
|
Phase 4 | |
Recruiting |
NCT05408624 -
Pilot Study Evaluating Outpatient Management of Tubo-ovarian Abscesses
|
||
Completed |
NCT01241110 -
To Compare Ofloxacin With Azitromycin for Pelvic Inflammatory Disease (PID) Treatment
|
Phase 4 | |
Completed |
NCT00453349 -
A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease
|
Phase 3 | |
Recruiting |
NCT04234945 -
Effect of Prophylactic Antibiotics for Hysterosalpingography on Post Procedure Morbidity
|
N/A | |
Recruiting |
NCT06360965 -
Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain
|
N/A | |
Recruiting |
NCT05648747 -
Pelvic Inflammatory Disease in COVID-19 Era
|
||
Completed |
NCT01793584 -
Surgical Success After Laparoscopic vs Abdominal Hysterectomy
|
N/A | |
Completed |
NCT01299259 -
Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease
|
N/A | |
Completed |
NCT03054402 -
First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845
|
Phase 1 | |
Active, not recruiting |
NCT03828994 -
Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID II
|
N/A |